Orange Book product · Generic (ANDA)
LINAGLIPTIN AND METFORMIN HYDROCHLORIDE
LINAGLIPTIN; METFORMIN HYDROCHLORIDE
At a glance
Aug 30, 2021
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Aug 30, 2021
4 yr 10 mo ago
Today
Pharmaceutical detail
Active ingredient
LINAGLIPTIN; METFORMIN HYDROCHLORIDE
Strength
2.5MG;1GM
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
ANDA 208336
Product number
003
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of LINAGLIPTIN; METFORMIN HYDROCHLORIDE
- 2016JENTADUETO XRBrand (NDA)
NDA 208026 · BOEHRINGER INGELHEIM
- 2012JENTADUETOBrand (NDA)
NDA 201281 · BOEHRINGER INGELHEIM
- 2025LINAGLIPTIN AND METFORMIN HYDROCHLORIDEGeneric (ANDA)
ANDA 208427 · DR REDDYS
- 2025LINAGLIPTIN AND METFORMIN HYDROCHLORIDEGeneric (ANDA)
ANDA 208459 · MSN
- 2023LINAGLIPTIN AND METFORMIN HYDROCHLORIDEGeneric (ANDA)
ANDA 208449 · ZYDUS PHARMS
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
